{"preliminary_commentary":{"by_channel":{"x_thread":11},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06578559\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"BRICKET","nct_id":"NCT06578559","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bricket-nct06578559. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"BRICKET","arms":[{"description":null,"label":"Encorafenib + Cetuximab","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC","Pierre Fabre Laboratories"],"completion_date":{"date":"2026-12-01","type":"ESTIMATED"},"conditions":["Colorectal Cancer"],"enrollment":{"count":16,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cetuximab","otherNames":[],"type":"DRUG"},{"name":"Encorafenib","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-09","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","official_title":"Single Arm Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients With BRAF V600E Mutated mCRC (BRICKET)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-05-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"8 months after the enrollment of the last patient."}],"references":[],"start_date":{"date":"2024-07-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","url":"https://clinicaltrials.gov/study/NCT06578559"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bricket-nct06578559"}